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Abstract
In less than two decades, first-pass perfusion cardiovascular magnetic resonance (CMR) has
undergone a wide range of changes with the development and availability of improved hardware,
software, and contrast agents, in concert with a better understanding of the mechanisms of
contrast enhancement. The following review provides a perspective of the historical development
of first-pass CMR, the developments in pulse sequence design and contrast agents, the relevant
animal models used in early preclinical studies, the mechanism of artifacts, the differences between
1.5T and 3T scanning, and the relevant clinical applications and protocols. This comprehensive
overview includes a summary of the past clinical performance of first-pass perfusion CMR and
current clinical applications using state-of-the-art methodologies.
Introduction
The clinical assessment of myocardial perfusion plays a
central role in the diagnosis, management, and prognosis
of ischemic heart disease patients. Whereas X-ray angiog-
raphy demonstrates the patency of the coronary arteries,
perfusion imaging detects the downstream microvascular
blood flow within the myocardium. Single photon emis-
sion computed tomographic (SPECT) imaging of myocar-
dial perfusion with 201TI or 99mTc-labeled agents is an
established clinical standard [1-4], but has relatively poor
spatial resolution, suffers from soft tissue attenuation arti-
facts, is not quantitative, and delivers a significant dose of
ionizing radiation[1]. Positron emission tomography
(PET) overcomes some of the limitations of SPECT; how-
ever, availability is restricted to sites with a cyclotron for
supplying short-half-life radiotracers. Echocardiography-
based perfusion is another technique but has limited
acoustic windows, low spatial resolution, and concerns
exist about contrast agent administration.
Myocardial perfusion imaging by first-pass contrast-
enhanced cardiovascular magnetic resonance (CMR) was
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sion-recovery gradient-echo imaging after injection of a
bolus of Gd-DTPA to observe contrast agent transit
through the cardiac chambers and myocardium[5]. Subse-
quently, the technique has undergone continuous techni-
cal development, experimental validation, and clinical
evaluation. Technical developments have occurred in the
areas of MR hardware (gradient systems, magnetic field
strength, radiofrequency coil arrays), pulse sequence
design, new contrast agents, and perfusion analysis meth-
ods. Evaluation has included preclinical imaging in ani-
mal models of ischemic heart disease, as well as clinical
studies. While the earliest CMR studies had limitations,
such as poor slice coverage and low temporal resolution,
recent clinical studies show that CMR now compares quite
favorably to SPECT and PET [6-8].
In this article, technical issues related to pulse sequences,
contrast agents, and analysis methods are discussed. Both
visual interpretation of images and quantitative analysis
methods are described. A review of preclinical and clinical
evaluation studies is also provided. In addition, practical
clinical matters such as safety, patient monitoring, and
proper training of personnel are covered. The article also
addresses some remaining unanswered questions: Will a
field strength of 3T be advantageous compared to 1.5T?
Given the expense in time and effort, is quantitative anal-
ysis better? Will we eventually understand and resolve the
confounding dark rim artifact?
Contrast agents
There are two major classes of contrast agents used for
first-pass perfusion imaging. The extravascular, extracellu-
lar class of agents were the first agents approved for clini-
cal use. Due to the small size of these agents, they rapidly
diffuse from the vascular space to the extravascular space.
While a wide range of agents have been used, including
manganese, gadolinium, and dysprosium, gadolinium-
based agents are the only clinically approved agents, albeit
primarily for brain and body imaging.
Due to its seven unpaired electrons, gadolinium is one of
the most effective paramagnetic agents[9]. However, due
to the extreme toxicity of free gadolinium, gadolinium is
always chelated. Paramagnetic contrast agents alter the
local magnetic field and thereby enhance the relaxation
rate of water protons in close proximity to the contrast
agent. Thus, intravenous delivery of low doses of para-
magnetic agents results in enhanced signal in T1-weighted
images in the tissues that are perfused. For low doses of
paramagnetic agents, an approximately linear relation-
ship between the image intensity and contrast agent con-
centration exists[10]. For cardiovascular imaging, the
dosage is often not kept low enough for this linearity
assumption to apply. However, the dosage is sufficient
low such that T2 and T2* effects do not predominate
throughout the scan. Thus, perfused tissue appears
brighter during the first pass of the gadolinium-based con-
trast agent[5]. While extravascular, extracellular contrast
agents are excluded from the intracellular space, water can
exchange between the intravascular and extracellular and
intracellular spaces. Thus, the effective concentration of
contrast agent in the tissue will be lower than the "true"
intravascular and extracellular concentrations.
The second major class of first-pass perfusion agents,
which are also primarily gadolinium-based, are the intra-
vascular agents. Diffusion from the vascular space is
inhibited by the large size of these agents. Their large size
also effectively decreases tumbling rates, resulting in a
higher relaxivity than the extravascular, extracellular
agents. One intravascular agent, trisodium- [2-(R)-[(4,4-
diphenylcyclohexyl) phosphono oxymethyl]-diethylene-
triaminepentaacetato) (aquo) gadolinium (III) (Vasovist,
Schering AG) is currently approved for use in Europe. This
agent reversibly binds to albumin in the plasma, effec-
tively resulting in a macromolecular, intravascular MR
contrast agent. While intravascular gadolinium-based
contrast agents were initially developed for MR angiogra-
phy, several groups have identified advantages of these
agents for first-pass perfusion imaging [11-14].
Animal cardiovascular disease models for perfusion 
imaging
To test new contrast agents and validate new imaging
sequences, phantoms and animal models of human cardi-
ovascular disease are often employed. First-pass perfusion
imaging of the heart using contrast agents on clinical scan-
ners has only been performed in larger animals, e.g., dogs,
sheep, and pigs, due to their lower heart rates and larger
cardiac size than murine models.
When considering animal models for human cardiovascu-
lar disease, one of the biggest concerns is whether the
degree of collateral circulation mimics man. Maxwell et al.
demonstrated that dogs and cats possess the greatest cor-
onary collateral flow after acute ischemia, with pigs pos-
sessing the least, and rats, rabbits, and sheep intermediate
between dogs and pigs[15]. There are also gradients in
perfusion across the heart wall, such that the high subepi-
cardial flow in dogs leads to non-transmural, subendocar-
dial infarcts with acute coronary occlusion, whereas pigs
typically have lower epicardial flow and develop transmu-
ral infarctions[16]. On the other hand, rats typically
develop non-transmural infarcts that do not extend to the
subendocardium. The largest determinant of whether tis-
sue is reversibly or irreversibly damaged is the duration of
occlusion. The earliest studies of contrast-enhanced, first-
pass perfusion imaging examined acute infarction animal
models that were either reperfused or permanentlyPage 2 of 18
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abnormalities without infarction have relied on models
that either limit epicardial artery blood flow or study the
effects of short-term coronary artery occlusion followed
by reperfusion [14,17,18]. Another approach is to study
perfusion pathways that develop with collateral vessel for-
mation in acute angina. Extensive studies in swine, who
lack native collaterals, have used an ameroid occluder,
placed around coronary artery branches [19]. Thus, ani-
mal models may provide a platform for validation of per-
fusion image pulse sequences and analysis techniques,
but the limitations of these models must be understood
for translation to the clinical realm.
Pulse sequences
The imaging pulse sequence is critical in determining the
image contrast, spatial resolution, and coverage and influ-
ences the potential for quantification and/or the presence
of artifacts. This section reviews the basics; a more com-
prehensive review of perfusion imaging sequences was
recently published by Kellman and Arai [20]. The basic
requirements of a first-pass myocardial perfusion imaging
pulse sequence are to provide: 1) strong T1 contrast; 2)
coverage of relevant myocardial segments; and 3) ade-
quate spatial resolution. Figure 1 contains a schematic of
a typical first-pass imaging sequence.
To provide T1 contrast, inversion recovery (IR) was the
first contrast preparation to be used, but was limited to
one or a few slices and proved sensitive to heart rate vari-
ation. Saturation recovery (SR) has emerged as the current
standard because contrast is theoretically independent of
the magnetization "history," e.g., heart rate and previous
acquisitions, and a higher numbers of slices (such as six to
eight) can be provided with interleaved acquisitions. SR is
typically implemented using a non-selective 90 degree
radiofrequency (RF) excitation followed by a gradient
crusher. This approach can be sensitive to variations in the
transmitted RF field[21], which has recently led to the use
of pulse trains, composite RF pulses, and B1-insensitive
rotation pulses (e.g., BIR-4), that provide more uniform
saturation in practice, albeit with increased RF heating.
Coverage of relevant myocardial segments is achieved
using an interleaved acquisition of arbitrarily oriented
slices. In Figure 1, six slices are acquired with a temporal
resolution of 2 R-R intervals. This could, for example,
include six short-axis slices or four short-axis slices plus
two-chamber and four-chamber long-axis slices. Note that
the slices have different cardiac phases, but each slice is
acquired repeatedly at the same cardiac phase. Slices
obtained during systole have the advantage of increased
myocardial thickness (i.e., more pixels across the wall),
while those obtained during the relatively stable cardiac
phases (e.g. mid-diastole and end-systole) have the
advantage of reduced motion artifacts. When the patient's
heart rate is elevated, the number of slices per R-R may
need to be reduced. With the goal of identifying large-ves-
Typical first-pass perfusion pulse sequenceFigure 1
Typical first-pass perfusion pulse sequence. (A) Acquisitions are cardiac gated using ECG signals. Multiple slices are acquired 
consecutively (shown: 6 slices every 2 R-R intervals). This is repeated continuously during the first-pass and washout of the 
contrast agent. (B) T1 contrast is generated using a saturation pulse (dark gray) followed by fast imaging of each slice (light 
gray) using gradient echo, gradient echo-planar, or steady state free precession acquisitions. Image contrast is primarily deter-
mined by the saturation recovery time, labeled TSR.Page 3 of 18
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goal of characterizing the extent of disease, there have
been recent attempts at providing contiguous whole-heart
coverage (similar to what SPECT and PET provide) using
either a large number of 2D slices or native 3D encoding
[22].
In multislice perfusion imaging, the slice thickness is typ-
ically 5 to 10 mm, and in-plane resolution is typically 1.5
to 3 mm. Depending on the resolution, field-of-view
(FOV), and use of acceleration, image acquisition of each
slice can take on the order of 50 – 200 ms. This requires
an ultra-fast acquisition, usually based on gradient echo
(GRE), gradient echo-planar (GRE-EPI)[23,24], or bal-
anced steady-state free precession (SSFP). Parallel imaging
[25-27] is also widely used as a means for accelerating
image acquisition. SSFP provides a higher signal-to-noise
ratio compared to GRE, but can suffer from off-resonance
artifacts that limit the repetition time (TR). GRE is the
basis of today's most robust protocols at 1.5T and 3T,
while SSFP has produced promising results at 1.5T [28].
Perfusion quantification is an active area of investigation
(see "Image Analysis" section) that can require a modified
acquisition. For example, measurements of regional myo-
cardial blood flow (in ml/g/min) can be made using time-
intensity curve deconvolution with a measured arterial
input function (AIF), usually from the left ventricular cav-
ity or ascending aorta[29,30]. Measurement of the true
AIF is affected by short T1s and T2* effects[31] that occur
with high contrast agent concentrations during bolus con-
trast agent passage in the blood pool. This has led to two
imaging strategies: 1) the "dual-bolus" method[32,33],
which involves AIF measurement during a separate low-
dose injection (1/10th or 1/20th the dose) prior to the full-
dose injection used for the measurement of myocardial
enhancement and 2) the "dual-sequence" method [34-
36], which replaces one of the imaging slices with an AIF
measurement slice that employs an acquisition that
avoids the saturation and T2* effects at high concentra-
tions.
Artifacts
Several artifacts can occur in first-pass perfusion imaging
that must be recognized in order to correctly interpret the
images qualitatively. The most prominent and trouble-
some artifact is the dark rim artifact (DRA). Recognizing
the causes of the DRA and other artifacts can aid in adjust-
ing the imaging parameters to minimize the consequences
of the artifacts.
The dark rim artifact
In some perfusion scans, a transient dark rim artifact is vis-
ible in the subendocardial layer, which can mimic a
hypoperfused area. An experienced observer can differen-
tiate between the DRA and a real perfusion defect by the
transient behaviour of the DRA. DRAs normally last for a
few heart beats, and vary temporally as the contrast bolus
passes through the left ventricle blood pool, while a real
perfusion defect tends to be visible for a longer duration
of the imaging (Figure 2) [37]. However, a mild perfusion
defect which "fills in" quickly is often difficult to identify
in the presence of artifact. Another property of this artifact
is that the signal intensity drops below the baseline signal,
i.e., below the signal before the contrast arrival [38,39].
Although a visual assessment can be used to identify an
artifact, a semi-quantitative or quantitative analysis can
become complex and erroneously estimate blood flow
when DRAs are present. Therefore, DRAs should be
avoided whenever possible.
Usually the perfusion sequence is acquired at rest and
stress. The DRA may be altered by faster cardiac motion
and a more concentrated Gd bolus due to increased car-
diac function at stress, leading to increased left ventricular
(LV) blood pool signal and more artifact at the margin of
the blood pool. However, the rest scan should not be
taken as a guarantee against DRA. The effect of residual
contrast agent in the second perfusion series should also
be considered.
Several possible causes have been suggested for DRAs. Di
Bella et al [40]. and others have suggested the possibility
of the artifact being produced largely by Gibbs ringing in
the phase encode direction (direction with the lowest res-
olution) at the blood-myocardial interface. A Fourier
transform of a finite signal has inherent difficulty in rep-
resenting a discontinuity; therefore, it will not reconstruct
sharp edges perfectly and will always have at least a 9%
(arising from the Wilbraham-Gibbs constant) signal vari-
ation (undershoot and overshoot) near the edge. A DRA
caused by Gibbs ringing would be dependent on the con-
trast between the LV and the myocardium; this could be
the reason that the intensity of the artifact varies tempo-
rally with the contrast between the blood pool and the
myocardium, (Figure 3 and Additional file 1). This expla-
nation is consistent with the higher concentration of the
contrast agent in the heart with stress, increasing the
Gibbs ringing at the endocardial border. The same effect is
expected from a higher injection rate of the contrast agent.
Balanced SSFP sequences are the most likely to suffer from
Gibbs because they produce a higher signal intensity dif-
ference between the blood pool and myocardium. If the
spatial resolution is sufficiently low, Gibbs ringing could
be severe enough to affect the entire interventricular sep-
tum, particularly during diastole. An obvious solution to
avoid Gibbs ringing is to increase resolution, sampling
larger regions of k-space. However, due to time con-
straints in cardiac imaging, this may not be possible. Par-
allel imaging can be used to increase resolution withoutPage 4 of 18
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the signal-to-noise ratio (SNR) decreases. Another option
to reduce Gibbs ringing is to filter the k-space with a win-
dow function, with the trade-off of lowering spatial reso-
lution.
The work done by Arai,[37] Fenchel et al.,[41] and Sch-
reiber et al. [39] attributes magnetic susceptibility, associ-
ated with the concentration of Gd-DTPA in the bolus, as a
possible cause for the DRA. Increased distortions in the
magnetic field around boundaries may cause dephasing
in individual voxels and possible signal misregistration
due to alterations in the Larmor frequency. Albert et
al.[42] studied the mechanism of bulk magnetic suscepti-
bility induced by a contrast agent bolus injection. This
study showed that, in an approximation to an infinitely
long right cylinder (resembling the LV blood pool and the
myocardial wall), the magnetic field of the surroundings
of the cylinder is distorted with the passage of a paramag-
netic substance inside the cylinder. This effect is also
dependent on the orientation of the cylinder in relation to
the main magnetic field, B0. Thus, the susceptibility
change is dependent on the heart orientation in relation
to B0, which will vary from patient to patient. A change of
magnetic susceptibility, caused by the arrival of the Gd in
the LV blood pool, in the DRA region was measured by
Schreiber et al.[39] Gibbs ringing was dismissed due to
the particular orientation of the artifact. The artifact was in
fact only visible when using a b-SSFP sequence, due to its
susceptibility sensitivity that can be avoided by decreasing
TR. The use of a high dose of contrast agent will also more
likely contribute to field distortion. The increase in the Gd
concentration at stress is therefore more likely to produce
a susceptibility artifact.
Banding artifacts at tissue boundaries may occur when the
object moves between the acquisitions of different phase
encode lines and could be another possible origin of the
Comparison between a dark rim artifact (DRA, top) and a real perfusion defect (bottom) from two different patientsFigure 2
Comparison between a dark rim artifact (DRA, top) and a real perfusion defect (bottom) from two different patients. From left 
to right are shown the contrast arrival to the left ventricle, the myocardium, and finally recirculation. A DRA artifact usually 
lasts for a few heartbeats while a real defect tends to be more persistent.Page 5 of 18
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by a factor equal to the square root of the acceleration
parameter. This study also showed that the direction of
the artifact is in the phase encode direction if the motion
is in that direction, or is oblique to the frequency encode
direction in case of motion in the latter direction. Simula-
tions of the intensity profile of a tissue boundary, mod-
eled as a step function, showed that when sequential
ordering of k-space data acquisition is used the oscilla-
tions occur in the brighter parts of the image, independent
of the motion direction; sequential ordering was preferred
to a centric ordering due to lower artifact amplitude [43].
Motion will result in oscillations in the pixel values along
the borders of different tissues with different intensities,
making it a good contender for a cause of DRA. Again, this
artifact correlates with the brightness difference between
blood and myocardium. A likely increase of motion arti-
facts is expected during stress, as discussed above.
Another possible origin for DRA is the non-uniform raw
k-space data weighting in the phase-encode direction, i.e.,
signal variations during the acquisition [20]. Distortions
in the point spread function along the phase-encode
direction result, due to data acquisition prior to reaching
the steady state. A dependency on T1, the time delay
between the readout and the saturation pulse, the
sequence used, and the flip angle will occur. Because the
LV blood pool and the myocardium have different T1s, a
DRA can be formed in the boundary between them. A pos-
sible way to minimize this artifact is to use an optimized
transition to equilibrium like the one used by Hennig et
al. [44].
Partial volume effects may also produce a DRA at the bor-
der between the LV blood pool and the endocardium.
Using an inversion recovery preparation at certain inver-
sion delays, the phases of both tissues can be opposite,
resulting in signal cancellation at this boundary. How-
ever, this artifact would be expected to appear around the
entire border [20,40]. A larger partial volume artifact
might appear in the apical slice, where the myocardial
wall might not be perpendicular to the imaging plane,
Simulation of a short axis line profileFig re 3
Simulation of a short axis line profile. Comparison between a high and a low contrast (between the LV blood and the myocar-
dium) line profile. Signal oscillations are higher for the high contrast image, as expected from the Gibbs truncation theory. (See 
Additional file 1.)Page 6 of 18
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pool in the same voxel.
The most frequently used pulse sequences for myocardial
perfusion studies have been studied to determine which
are most prone to DRA. Elkington et al.[45] compared a
hybrid-echoplanar imaging sequence with spoiled GRE in
patients with CAD and found no significant difference in
artifact scoring between the two. Wang et al.[28] com-
pared a b-SSFP sequence with spoiled GRE and segmented
EPI in volunteers with no clinical history of CAD. The
study found a higher DRA score for the bSSFP sequence
when compared to the other two sequences. A similar
study using healthy subjects found a higher score for DRA
when using a b-SSFP sequence, this time compared to
spoiled GRE [41].
Recently, Klem et al. described a method for diagnosis of
coronary artery disease (CAD) where adenosine-stress and
rest perfusion cardiovascular magnetic resonance (CMR)
are combined with late gadolinium enhancement (LGE)
CMR [46]. This method particularly implies that per-
fusion defects detected both at rest and stress combined
with no detection of infarcted areas on the late gadolin-
ium enhancement should be interpreted as an DRA.
Other artifacts
Although DRAs represent the most serious artifact in myo-
cardial perfusion imaging, several other types of artifacts
may also occur. Semiquantitative and quantitative analy-
ses of myocardial perfusion studies assume a perfect mag-
netisation preparation; qualitative analysis will also
improve with a complete saturation. Saturation pulses
are, in general, not perfect, due to B0 and B1 field inho-
mogeneities, leaving regional magnetisation residues that
alter the apparent T1 relaxation times and eventually lead
to errors in quantifying perfusion in those areas. Kim et
al[21] evaluated favourably the use of a B1 Insensitive
Rotation (BIR-4) saturation pulse to account for the field
distortions. This RF pulse is effective in producing a com-
plete saturation at 1.5T. High field strengths will, very
likely, make it even more useful, but with additional spe-
cific absorption rate (SAR) concerns.
A common artifact seen in perfusion studies is wrap arti-
fact, where one part of the anatomy might be encoded in
the same position as another, creating signal interference.
Several solutions exist, such as in-plane rotation of the
phase/frequency encode direction or increasing the phase-
encode field of view. Parallel imaging techniques can also
produce artifacts, particularly spatially variant noise,
which is related to the position of the coils on the patient,
and aliasing due to errors in the sensitivity estimation of
the coils. Chemical shifts and N/2 artifacts can also be
problematic for GRE-EPI sequences. Therefore these
sequences usually incorporate fat suppression pulses and
phase correction reference scans, respectively.
1.5T vs. 3T issues
Whole body 3T scanners are increasing in availability,
prompting comparison between 1.5T and 3T for CMR.
Higher field strengths have the advantage of higher SNR,
but there are also a number of possible disadvantages that
could lead to artifacts in perfusion imaging. Firstly, both
the B0 and B1 field inhomogeneities are increased and
greater care has to be taken to reduce the impact of these.
Secondly, the T1 is increased and this, coupled with a
shorter T2*, could lead to a reduced signal and perfusion
contrast. The relaxivity of the commonly used Gd-DTPA is
3.7 mmol/L/s at 3T versus 4.1 mmol/L/s at 1.5T; therefore,
the T1 shortening effect of the contrast agent is reduced at
3T. Nevertheless, precontrast T1 is higher for higher fields,
making the difference of T1 before and after contrast
larger for high fields and enabling an overall better con-
trast to noise ratio (CNR) for myocardial enhancement
[36,47]. However, increases in SAR at 3T can significantly
limit any possible SNR gains.
An SNR increase of 109% was obtained by Gutberlet et al.
using a T1-weighted segmented EPI with an echo train
length of 4 at 3T when compared to 1.5T [48]. Araoz et al.
obtained an SNR of 82 ± 26 and 25 ± 8 for 3T and 1.5T,
respectively, at peak myocardial enhancement using an
interleaved notched saturation recovery gradient echo
pulse sequence with an echo train of 4 [49]. At clinical
doses of contrast agent, i.e., 0.1 mmol/kg, the SNR
increased in the myocardium, but the LV blood pool SNR
was similar between 3T and 1.5T, suggesting that an
increase in the Gd concentration creates T2* signal loss
that negates the increased signal at higher field strengths.
Hinton et al., using a cine true FISP sequence, compared
functional and morphological cardiac evaluations at 3T
and at 1.5T [50]. The CNR at 3T, using a much smaller flip
angle in order to avoid SAR limitations, was similar to the
one obtained in the 1.5T scans. Susceptibility artifacts
were also increased using the b-SSFP sequence. In order to
avoid the potential banding artifact, a short TR and per-
patient shimming is advised [51]. ECG triggering was
acceptable at both field strengths, based on no increased
motion artifacts in the images when comparing 1.5T to
3T.
SNR increase comes with the penalty of an increase in the
artifact-to-noise ratio (ANR). Artifacts that were already
present at 1.5T become more prominent at 3T, such as
errors in parallel imaging and a deficient crusher gradient
[51]. An increase of CNR in the endocardial boundary
would tend to make Gibbs ringing and motion artifacts
more visible, but the high SNR enables faster imaging and
reduced motion artifact. Chemical shift artifacts alsoPage 7 of 18
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bandwidth with an SNR penalty.
Another current problem with high-field systems is the
fact that imaging parameters, RF pulse profiles, and RF
coil designs have been extensively optimized at 1.5T
whereas 3T optimization is now only being per-
formed[51,52] As 3T scanners gain a wider market share,
this concern will most likely disappear. With an opti-
mized system, the values of increased SNR and CNR can
be utilized, making high-field systems a contender for car-
diovascular MRI.
Imaging protocols & indications
Imaging indications
Currently, the two major clinical indications for use of MR
perfusion imaging are: 1) the detection and sizing of
microvascular obstruction in patients after acute myocar-
dial infarction, and 2) the detection of ischemia in
patients with suspected coronary artery disease. In both
cases, perfusion imaging pulse sequences will likely be
used in combination with other pulse sequences, such as
segmented k-space cine sequences to allow assessment of
myocardial function, and inversion recovery sequences to
allow assessment of myocardial viability. However, since
the clinical objectives of CMR in these two groups of
patients are different, most investigators will use different
study protocols for each type of patient. Also, the image
parameters for each group of patients will likely differ to
accommodate for the different requirements in these two
clinical situations.
Evaluation of patients with acute myocardial infarction
In patients with acute MI, the main purpose of myocardial
perfusion imaging is the precise estimation of the size of
microvascular obstruction (no-reflow area),[53] if
present. A typical protocol, which might be used for
assessment of microvascular obstruction in patients with
acute MI, is illustrated in Figure 4. Resting perfusion imag-
ing is performed during bolus injection (3–4 ml/min) of
a low dose (0.05–0.1 mmol/kg) of Gd chelate. Since the
purpose of this resting perfusion study is accurate sizing of
the area of microvascular obstruction/no-reflow, one
must increase the spatial coverage and compromise tem-
poral resolution. Since the perfusion defects due to micro-
vascular obstruction fill in relatively slowly, temporal
resolution is less important than for stress perfusion stud-
ies. Typically, dynamic imaging with full coverage of the
entire heart, e. g., 8–10 short axis slices, is performed with
a repetition rate every 2 or 3 heart beats. After the comple-
tion of the rest perfusion study, additional contrast can be
infused for a total dose of 0.15–0.2 mmol/kg for subse-
quent LGE CMR images for infarct sizing. These LGE
images are acquired 10–20 minutes after the contrast
injection, with inversion recovery gradient pulse
sequences. An alternative approach is to just obtain single
shot LGE images to visualize microvascular obstruction.
However, the time between first-pass perfusion sequence
and LGE images can be used to acquire functional SSFP
cine images. Since image contrast in SSFP is determined
by the T2/T1 ratio of the tissue, SSFP image quality is often
not significantly impaired.
Evaluation of patients with suspected coronary artery disease
Suspected coronary artery disease can be most dramati-
cally demonstrated during stress-induced ischemia on MR
perfusion imaging performed during maximal coronary
vasodilation. Vasodilatation can be induced by infusion
of either dipyridamole or adenosine. Both agents act
through stimulation of A2 receptors in the microvascula-
ture. Adenosine is the direct agonist of this receptor. On
the other hand, dipyridamole is a pro-drug, whose liver
metabolite exerts its effect by an indirect mechanism on
the endothelium – blocking the cellular reuptake of ade-
nosine and inhibition of adenosine deaminase in
endothelial cells, which leads to increased extracellular
concentrations of adenosine. The stimulation of the A2
receptors relaxes the resistive arterioles, which normally
autoregulate myocardial perfusion relative to coronary
perfusion pressure. In normal non-ischemic myocardium,
this results in maximal hyperemic vasodilation with an
increase of myocardial perfusion without changes in myo-
cardial blood volume [54]. In myocardium subtended by
a signficant epicardial coronary stenosis, the magnitude of
the perfusion increase during vasodilation is compro-
mised compared to normal myocardium, because of the
drop of coronary perfusion pressure downstream of the
Typical protocol for assessing extent of microvascular obstruction with rest first-pass perfusion imagingFigure 4
Typical protocol for assessing extent of microvascular 
obstruction with rest first-pass perfusion imaging. An alter-
nate method of imaging microvascular obstruction is single 
shot late gadolinium enhancement.Page 8 of 18
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lary closure, reduced perfusion, and reduced blood vol-
ume during hyperemia, which all translates into a slower
arrival and lower contrast agent concentration in the
ischemic as compared to normal myocardium. Thus, the
ischemic regions demonstrate reduced signal intensity rel-
ative to the normal myocardium on T1-weighted images
during vasodilation and appear as a perfusion defect [54].
Two different protocols are currently used for the infusion
of dipyridamole. The low-dose injection protocol consists
of an infusion of a total dose of 0.56 mg/kg dipyridamole
in 4 minutes, with imaging started immediately after com-
pletion of the 4 minute infusion. The high-dose injection
protocol adds a second injection of 0.28 mg/kg dypyrida-
mole for 2 minutes duration, commencing at 8 minutes
after the beginning of the first injection. Thus, a total dose
of 0.84 mg/kg dipyridamole is administrated in this high-
dose dipyridamole infusion protocol. Imaging is initiated
at the end of the second infusion, i.e., 10 minutes after the
beginning of the first dipyridamole infusion. The advan-
tage of the high-dose dipyridamole infusion protocol is a
more intense, longer lasting and more predictive vasodil-
atation response than that obtained by the low-dose pro-
tocol.
For the adenosine infusion protocol, adenosine is injected
at a rate of 0.14 mg/kg/min, typically for 3–6 minutes for
a total dose of 0.48 to 0.84 mg/kg, with imaging during
the terminal portion of the adenosine infusion. Adenos-
ine and contrast are administered via separate IVs to avoid
large bolus drug delivery that increases risk of heart block.
The adenosine infusion can be stopped when the contrast
is completed. Both dipyridamole and adenosine can cause
similar side effects, which may include light flushing,
mild chest discomfort, and headache. Patients with signif-
icant coronary artery disease may experience angina pec-
toris. More serious side effects include atrioventricular
(A) Typical first-pass perfusion protocol for adenosine stress perfusion CMRFigure 5
(A) Typical first-pass perfusion protocol for adenosine stress perfusion CMR. (B) Typical first- pass perfusion protocol for dipy-
ridamole stress perfusion imaging.
(a)
(b)Page 9 of 18
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erfusion with potential neurological symptoms in the
presence of significant carotid stenosis.
The advantage of dipyridamole over adenosine is the
lower cost and longer duration of vasodilation with a half-
life of ~30 minutes versus < 10 seconds for adenosine,
which gives a longer time period for performing the per-
fusion imaging. This longer half-life of dipyridamole can
be associated with a longer duration of potential side
effects that are not as self-limiting as adenosine. On the
other hand, the short half-life of adenosine may give less
time to respond to potential side effects. Because of the
potential side effects, patients need to be monitored
before, during, and after stress protocols, and equipment
and qualified personnel for life support and resuscitation
needs to be available. Since the vasodilating effects of
both dipyridamole and adenosine can be abolished by
ingestion of xanthine inhibitors, patients should with-
hold caffeinated beverages and theophylline for 24 hours
prior to imaging [55]. Dipyridamole and adenosine are
contraindicated in patients with severe conduction altera-
tions, obstructive pulmonary disease (COPD and asthma)
and severe carotid stenosis. Neither drug should be
administered to pregnant women.
After induction of vasodilation by either adenosine or
dipyridamole, first-pass perfusion imaging is performed
during intravenous bolus injection of a gadolinium-based
contrast agent. The objective of the test is the detection of
perfusion defects in the ischemic area. Due to the extravas-
cular distribution of most clinically approved contrast
agents, such perfusion defects persist very briefly after
bolus injection, before disappearing due to redistribution
into the extravascular space. Hence, stress MR perfusion
imaging requires very rapid image acquisitions. The focus
of the pulse sequence will thus be maximal temporal res-
olution, at the cost of left ventricular coverage and spatial
resolution. The best available perfusion sequences typi-
cally allow 3–4 short and/or long-axis slices to be
acquired in a dynamic mode with a temporal repetition
rate of every heart beat.
Typical MR stress perfusion protocols are illustrated in
Figure 5. Most protocols consist of stress and rest per-
fusion studies, to allow distinction of perfusion defects
from ischemia versus image artifacts. The optimal order of
rest and stress perfusion test may be different for adenos-
ine versus dipyridamole protocols. Due to the short half-
life of adenosine, it may be better to perform the stress
study first so that the stress perfusion measurement is not
contaminated by residual gadolinium injected at rest.
Indeed, if resting perfusion is performed first, there is a
potential risk that Gd might accumulate in infarcted areas
and mask the inducible ischemic areas in a subsequent
stress test. However, in the case of dipyridamole, it may be
better to first perform the resting study and then the stress
study, since the long-lasting vasodilatory effect of dipyri-
damole can persist and delay the rest study by more than
15 minutes. Thus, adenosine may be the preferred vasodi-
lator for MR perfusion studies.
Staffing and technical components required for patient 
stress testing
Patient safety during myocardial perfusion assessment
requires appropriate staffing and technical considera-
tions. The three types of staff typically involved in per-
forming a stress CMR examination include technologist,
nurse, and physician. The nurse and physician should be
certified in basic and advanced cardiac life support with
experience in anticipating, recognizing, and managing
cardiac events that may occur secondary to or independ-
ently of pharmaceutical-induced effects. This is facilitated
by having MR-compatible monitoring equipment in the
scanner room with an additional display outside the
room if needed. The minimum monitoring needs include
continuous electrocardiographic display and heart rate
measurement as well as periodic blood pressure record-
ing. Capabilities for noninvasive oximetry are often help-
ful, particularly for the patient with obstructive lung
disease of uncertain severity undergoing stress with
vasodilators that may produce bronchoconstrictive
effects. Weight-based vasodilator doses for stress are typi-
cally prepared by the pharmacy staff and delivered to the
MR lab at the start of the procedure. In the MR lab area,
there is also a point-of-care automated medication storage
unit accessible by the clinical staff that is stocked with
medications such as aminophylline, metoprolol, and
lidocaine that may be needed for acute reversal or therapy
of complications. In instances requiring defibrillation or
resuscitation, there should be a plan in place that clearly
delineates individual responsibilities when a patient
needs to be brought out of the scanner room. One indi-
vidual is typically responsible for patient transferal,
another goes to get the resuscitation equipment or "crash
cart", and the physician is responsible for directing appro-
priate inteventions. Such events may trigger the arrival of
many individuals, who arrive to help with resuscitation
but may not be facile with principles of MR safety. Thus,
vigilance by the MR staff is required.
Pre- and post-procedure patient assessment
Prior to the exam, the nurse typically screens the patient
for clinical history that would preclude administration of
adenosine or dipyridamole. This is done in conjunction
with screening for MR contraindications, such as presence
of ferromagnetic foreign body, aneurysm clip, intraorbital
metal, or non-MR compatible implant. As noted earlier, a
history of obstructive airway disease or conduction abnor-
malities should prompt the discussion of whether adeno-Page 10 of 18
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baseline electrocardiogram (ECG) is acquired prior to the
MRI examination.
After the exam, the patient is returned to the preparatory/
recover area outside the scanner room where the nurse
repeats a 12-lead ECG. The yield of this tracing is fairly
low, given the rarity of ST changes due to adenosine. How-
ever, ischemic ECG changes resulting from adenosine por-
tend a high likelihood of significant obstructive coronary
artery disease. A post-procedure blood pressure measure-
ment should also be documented, particularly if there was
any significant blood pressure deviation during the exam.
Image analysis
Qualitative interpretation
Qualitative interpretation of perfusion CMR images
remains the mainstay of clinical reporting in 2007. Fur-
thermore, stress perfusion interpretation almost always
requires concomitant acquisition and interpretation of
LGE images. A step-wise algorithm that begins with review
of LGE images, followed by stress and rest perfusion
images works well for overall classification of presence or
absence of epicardial coronary disease in most cases [46].
After carefully identifying the presence and extent of inf-
arct scar on LGE imaging, the interpreting physician can
better determine whether perfusion defects match regions
of scar vs. those that extend beyond the scar. In the
absence of scar or artifact (see below), uniform myocar-
dial enhancement throughout the myocardium in all
slices at rest and with vasodilator stress indicates absence
of ischemia. With LGE in a region and corresponding
defect on stress perfusion images, the interpretation of
"fixed defect, no ischemia" is appropriate. When a region
demonstrates stress perfusion abnormality that normal-
izes at rest without LGE, the interpretation of "positive for
ischemia" follows, barring artifact (Figure 6). A region of
perfusion abnormality with stress that corresponds to the
scar on LGE but subtends a greater myocardial extent war-
rants description as "infarct with peri-infarct ischemia."
Clinically, this is helpful to the referring physician when
judging whether or not to revascularize a chronically
occluded vessel (Figure 7). Viable myocardium based on
transmural extent of scar along with extent of ischemia
may help guide assessment of the need for and likely
response to revascularization in such cases [56]. Finally,
some patients undergoing stress CMR may have circum-
ferential subendocardial ischemia. Angiography may be
required to classify diffuse subendocardial perfusion
abnormality with vasodilator stress as multivessel or left
mainstem coronary artery disease versus microvascular
disease, as has been described in patients with syndrome
X [57].
Myocardial perfusion CMR was performed in a 43 year-old female to evaluate exertional chest pressureFigure 6
Myocardial perfusion CMR was performed in a 43 year-old female to evaluate exertional chest pressure. Perfusion images 
obtained during intravenous infusion of adenosine (A) demonstrate severe hypoenhancement of the septum, anterior wall, and 
apex that is not present on resting perfusion imaging (B). Late gadolinium enhancement acquisitions are negative for hyperen-
hancement (C); together, these findings suggest severe myocardial ischemia in the distribution of the left anterior descending 
coronary artery without infarction. (D) Invasive coronary angiography confirms high-grade serial stenoses in the left anterior 
descending coronary artery. (See Additional file 2.)Page 11 of 18
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Image analysis for quantitative MRI perfusion studies
In analyzing first-pass contrast enhancement images for
quantitative assessment of cardiac perfusion, we need to
be able to position a region of interest (ROI) within the
wall, in order to follow the dynamic changes in MRI signal
intensity. While in principle this is straightforward, there
are some relevant issues that may need to be considered.
First, we need to position the ROI carefully, so as to avoid
contaminating the wall signal with signal from the adja-
cent blood. Another potential problem with ROI posi-
tioning can arise if there are premature ventricular beats,
leading to variability of the size of the ventricular cavity
and thus the position of the wall. Also, since patients are
often unable to hold their breath for the full duration of
the sequence of dynamic enhancement images, interac-
tively repositioning of the ROI on sequential images may
be needed to track a consistent portion of the heart wall.
First-pass myocardial perfusion CMR was performed in a 75 year-old male with a history of bypass surgery seeking a second opinion regarding intervention for bypas graft dis aseigure 7
First-pass myocardial perfusion CMR was performed in a 75 year-old male with a history of bypass surgery seeking a second 
opinion regarding intervention for bypass graft disease. Perfusion images obtained during intravenous infusion of adenosine (A) 
demonstrates diffuse subendocardial perfusion abnormality not present on resting perfusion imaging (B). Late gadolinium 
enhancement acquisitions (C) show a small region of enhancement involving the lateral wall. Together, these findings suggested 
prior infarct with ischemia. His symptoms were controlled with optimization of anti-anginal medical therapies. (See Additional 
file 3.)Page 12 of 18
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model proposed by the American Heart Association, cor-
responding to the typical blood flow distributions of the
coronary arteries [58]. The epicardial and endocardial
borders of the heart are defined, and then the resulting
annular regions are divided into suitable septal and free
wall segments. As the subendocardial portion of the heart
wall is most vulnerable to ischemia, it can be useful to fur-
ther subdivide the segmental ROIs into endocardial and
epicardial halves.
As there is no absolute scale of image intensity in MR, and
there are many potential sources of variability of the
image intensity, an approach to standardize and repro-
ducibly quantify dynamic intensity changes is needed.
One approach is to acquire additional calibration images,
whose intensities must also be measured. For example,
acquiring a "proton density" image at the same location
can be used both to provide an "absolute" intensity scale
and to correct for shading due to the use of local surface
coils [59,60]. A separate noise image can also be acquired
for estimating possible noise bias in low intensity images
(as may be seen prior to the arrival of the contrast bolus
in the T1-weighted images).
In any attempt at quantitative analysis of dynamic first-
pass perfusion images, we need to be able to account for
the effect of potential variations in the rate, amount, and
timing of the delivery of the contrast agent in the blood
(the arterial input function) on the resulting enhance-
ment of the heart wall. One way to estimate the arterial
input function (AIF) is to position an ROI within the left
ventricular cavity, while minimizing contamination due
to volume averaging, and follow the sequential signal
changes in the blood.
Quantification of CMR perfusion
There are many potential problems associated with the
determination of contrast concentrations from serial MR
intensity measurements. First, the relationship between
contrast concentration and signal is nonlinear, and also
depends in a nonlinear way on the imaging parameters,
such as the time between the saturation pulse that pro-
duces the T1 weighting and the image data acquisition.
This nonlinearity can be particularly problematic when
the concentration of contrast agent is high, as during the
peak enhancement phase, as the response of the signal
intensity may be effectively saturated, leading to a ten-
dency to underestimate the concentration. Regional varia-
tions in the RF excitation field (B1) and the main
magnetic field of the MR system (B0) can produce a corre-
sponding variation of the amount of residual magnetiza-
tion left after the nominal saturation pulse, with a
resulting uncertainty of the amount of the contrast agent-
induced signal increase [21]. Finally, there may be some
uncertainty as to whether it is reasonable to assume that
all the water in the tissue is equally exposed to the contrast
agent ("fast exchange" condition) [61].
Assuming that we can determine the time course of the
contrast agent concentrations in the arterial blood and the
myocardium, calculation of the corresponding perfusion
blood flow and related parameters can then be done. A
hypothetical instantaneous bolus input ("impulse") of
contrast agent at the tissue arteriolar level would produce
a corresponding transient increase in the tissue concentra-
tion that would depend on the blood flow into the tissue,
and would last for at least the duration of the transit of the
labeled blood through the tissue. The mean transit time
(MTT) of an instantaneous bolus is given by the ratio of
the fractional blood volume of the tissue and the flow. As
conventional contrast agents can diffuse from the vascular
space into the extravascular space (but not into normal
cells), the observed transit will be longer than the nomi-
nal vascular MTT. Obviously, any delay or prolongation of
the delivery of the contrast agent to the tissue will be
directly reflected in the observed tissue response, effec-
tively being combined ("convolved") with the ideal
impulse response, and will also need to be accounted for.
A variety of approaches have been proposed to approxi-
mately correct the observed tissue enhancement for the
effects of the AIF. These include calculating various
parameters of the observed tissue enhancement curves,
such as the time of arrival of the contrast agent, the time
of the peak enhancement, and the slope of the enhance-
ment curve, and correcting them by subtracting or scaling
by the corresponding AIF parameters. The presence of
noise in the data and other experimental limitations can
lead to problems in reliably defining these parameters in
practice. Furthermore, these empirical estimates don't
allow a full calculation of the tissue transit effects or
extravascular exchange of the contrast agent. A potentially
better approach is to approximately mathematically undo
("deconvolve") the effects of the AIF from the observed
tissue response, in order to estimate the corresponding
underlying MTT and calculate the blood flow; a variety of
approaches have been proposed for carrying out such cal-
culations [29,62,63].
In light of the numerous obstacles outlined above, no
quantitative perfusion analysis technique has gained
widespread clinical use at this time. However, in research
endeavors and in some clinical settings, one may use a rel-
ative index of myocardial perfusion reserve [7,57,64,65].
For example, using semiautomatic delineation of endo-
cardial and epicardial left ventricular borders throughout
the phases of first-pass perfusion, with respiratory motion
correction as needed, rest and stress myocardial perfusion
slopes may be derived using Fermi-fitting of signal inten-Page 13 of 18
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slope as well as heart rate [57]. A Myocardial Perfusion
Reserve Index (MPRI) is then the ratio of stress to rest nor-
malized myocardial perfusion slopes.
Clinical interpretation of first-pass CMR perfusion
Cardiovascular MR perfusion imaging with rest and stress
acquisitions also helps answer a variety of clinical ques-
tions in the subacute or chronic setting. For example, the
patient with atypical chest pain in whom ischemic heart
disease is suspected may undergo rest/stress CMR per-
fusion imaging with LGE to define the presence or
absence of flow-limiting coronary artery disease as the
cause of symptoms. This is particularly helpful if there is
known coronary artery disease and prior infarction. The
superiority of CMR to delineate infarct scar becomes criti-
cal in providing this information in addition to extent of
ischemia [66]. In patients identified as having anatomic
lesions of uncertain hemodynamic significance by angiog-
raphy, CMR with rest/stress perfusion may be helpful to
define the angiographic lesion(s) producing impaired
myocardial blood flow under stress conditions.
Rest perfusion CMR in acute MI patients
Detection of microvascular obstruction can assist in the
distinction of chronic from acute infarcts, since microvas-
cular obstruction occurs exclusively in acute myocardial
infarction and disappears progressively over time [67].
The presence of microvascular obstruction in an infarcted
area can be a marker of non-viable tissue in which func-
tion rarely recovers [68-72]. More importantly the pres-
ence of microvascular obstruction has been shown to have
negative prognostic value in patients with acute infarcts
[67,73,74]. Patients who had infarcts with microvascular
obstruction were found to have significantly more events,
such as death and hospitalization for heart failure, and
increased adverse remodeling [73-75].
Stress perfusion CMR in patients with suspected coronary 
artery disease
Diagnosis of coronary artery disease in with stable chest pain
The results of nine studies of 618 patients, which reported
diagnostic accuracy on per-patient basis for detection of
coronary artery disease versus detection of invasive coro-
nary angiography, are summarized in Table 1. Overall, in
these studies, perfusion CMR had high sensitivity (89%),
specificity (81%), and accuracy (86%) for detection of sig-
nificant (> 75% diameter stenosis) coronary artery disease
on a per-patient basis. Similarly high accuracy was
reported in other single-center studies[64,76,77] on a seg-
mental basis alone.
At present, two multicenter studies have examined the
influence of contrast agent dose on diagnostic accuracy.
[78,79] Most studies have examined the diagnostic accu-
racy for detection of anatomical coronary artery stenosis
(defined either as > 50% or > 75% luminal diameter
reduction). The limitation of this approach is that func-
tional severity of a coronary stenosis may vary and depend
on parameters other than lumen diameter. Two studies
[7,80] compared flow reserve by CMR versus PET, the
non-invasive gold-standard at present, and demonstrated
a high correlation and diagnostic accuracy. In another
study, Rieber et al.[81] compared the diagnostic accuracy
of perfusion CMR versus angiographically measured frac-
tional flow reserve and reported good diagnostic accuracy
of perfusion CMR to this invasive gold-standard.
A few studies have compared diagnostic accuracy of CMR
versus other techniques for detection of coronary artery
disease. Ishida et al.[82] showed a higher diagnostic accu-
racy of perfusion CMR than SPECT for detection of signif-
icant CAD. Similarly, Sakuma at al.[8] observed a similar
higher diagnostic accuracy for CMR than for 201Tl SPECT.
Paetch et al.[83] reported similarly high sensitivity, specif-
icity, and accuracy compared to dobutamine stress MR for
detection of coronary artery disease.
Table 1: Diagnostic accuracy of perfusion MR for assessment of coronary artery disease
Author Remarks # of patients Prevalence of CAD Sensitivity (%) Specificity (%) Accuracy (%)
Schwitter et al. [7] upslope 57 65% 86% 85% 86%
Nagel et al. [90] upslope 84 51% 88% 90% 89%
Ishida et al. [82] 104 74% 90% 85% 88%
Wolff et al. [78] low dose group 26 54% 93% 75% 85%
Giang et al. [79] group 2 and 3 44 64% 93% 75% 86%
Paetsch et al. [83] upslope 79 67% 91% 62% 81%
Plein et al. [91] upslope 92 64% 88% 82% 86%
Sakuma et al. [8] visual 40 53% 81% 68% 75%
Klem et al. [46] visual: perfusion and late 
enhancement
92 40% 89% 87% 88%Page 14 of 18
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disease presenting to the emergency room
In a study of 135 patients, who presented to the emer-
gency department with chest pain, but without acute myo-
cardial infarction, Ingkanisorn et al.[84] reported that an
abnormal adenosine perfusion CMR exam had a 100%
sensitivity and 93% specificity for predicting future
events, such as coronary artery disease, new MI, or death.
This suggests that perfusion CMR could have a potential
role in selecting patients with high risk in the emergency
department.
Perfusion CMR in other diseases
Panting et al.[57] employed perfusion CMR to elucidate
the cause of chest pain in patients without significant cor-
onary artery disease or Syndrome X. A reduced flow
reserve was shown in the subendocardium, but not in the
subepicardium in these patients, suggesting a potential
ischemic origin for Syndrome X. A study by Vermeltfoort
et al.[85] did not confirm this finding, but a more recent
study by Lanza et al. was confirmative and showed Dop-
pler derived coronary flow abnormalities in the abnormal
regions identified by perfusion CMR [86]. In addition,
abnormalities in subendocardial perfusion have been
recently reported in patients with repaired aortic coarcta-
tion, a population that suffers early death due to myocar-
dial ischemia [87].
Prognostic value of stress perfusion CMR
Finally, perfusion CMR has also been shown to have pre-
dictive value in patients with coronary artery disease.
Indeed, Jahnke et al.79 evaluated the prognostic value of
this technique in 533 patients with chest pain or dyspnea
and suspected coronary artery disease in comparison to
dobutamine stress MR. Over a median follow-up of 2.3
years, ischemia by perfusion CMR was found to be the sin-
gle best predictor of cardiac death or nonfatal myocardial
infarctions and was superior to ischemia on dobutamine
stress CMR. Presence of a normal perfusion test was pre-
dictive of 99% chance of a 3 year event-free survival.
LGE/stress/rest perfusion vs. other approaches
It should be remembered that clinicians have choices
among several modalities when deciding whether or not
to refer individual patients for perfusion CMR examina-
tion, particularly stress perfusion imaging. The value
added by LGE imaging comes from its proven reliability in
delineating extent of infarcted myocardium[56] as well as
its superior ability to detect myocardial disease due to
other nonischemic cardiomyopathies [88]. Incorporating
other measurements, such as presence of significant valvu-
lar disease and velocity-encoded data to assess diastolic
function[89]1, allows a brief, single CMR exam to provide
comprehensive assessment for etiologies of cardiovascular
signs and symptoms that might otherwise require multi-
ple testing and, therefore, less cost-effective healthcare.
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